PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20446917-4 2010 In these conditions, abrogating specifically Pgp-mediated efflux in vitro revealed the remarkable and statistically significant cellular accumulation of imatinib (difference in cellular levels between Pgp-expressing and silenced cells, at high and low incubation concentration, respectively: 6.1 and 6.6), dasatinib (4.9 and 5.6), sunitinib (3.7 and 7.3) and sorafenib (1.2 and 1.4), confirming that these TKIs are all substrates of Pgp. Sunitinib 331-340 ATP binding cassette subfamily B member 1 Homo sapiens 45-48 22673043-1 2012 To elucidate the impact of genetic variations in breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (MDR1/ABCB1) on the pharmacokinetics of sunitinib, we carried out a pharmacogenetic study in a clinical setting and pharmacokinetic analysis using Abcg2(-/-), Abcb1a/1b(-/-) and Abcb1a/1b;Abcg2(-/-) mice. Sunitinib 154-163 ATP binding cassette subfamily B member 1 Homo sapiens 99-113 22673043-1 2012 To elucidate the impact of genetic variations in breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (MDR1/ABCB1) on the pharmacokinetics of sunitinib, we carried out a pharmacogenetic study in a clinical setting and pharmacokinetic analysis using Abcg2(-/-), Abcb1a/1b(-/-) and Abcb1a/1b;Abcg2(-/-) mice. Sunitinib 154-163 ATP binding cassette subfamily B member 1 Homo sapiens 115-119 22673043-1 2012 To elucidate the impact of genetic variations in breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (MDR1/ABCB1) on the pharmacokinetics of sunitinib, we carried out a pharmacogenetic study in a clinical setting and pharmacokinetic analysis using Abcg2(-/-), Abcb1a/1b(-/-) and Abcb1a/1b;Abcg2(-/-) mice. Sunitinib 154-163 ATP binding cassette subfamily B member 1 Homo sapiens 120-125 21351087-4 2012 In vitro, sunitinib was a good substrate of murine (mu)ABCG2 and a moderate substrate of human (hu)ABCB1 and huABCG2. Sunitinib 10-19 ATP binding cassette subfamily B member 1 Homo sapiens 99-104 20345483-4 2010 Sunitinib remarkably reversed BCRP-mediated and partially reversed P-gp-mediated drug resistance in the respective transfectants. Sunitinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 67-71 20345483-5 2010 The in vitro vesicle transport assay indicated that sunitinib competitively inhibited BCRP-mediated estrone 3-sulfate transport and P-gp-mediated vincristine transport. Sunitinib 52-61 ATP binding cassette subfamily B member 1 Homo sapiens 132-136 19773380-6 2009 Sorafenib and sunitinib showed concentration-dependent (1 and 10 micromol/L), low to moderate affinity for ABCB1 but were not affected by the other ABC transporters. Sunitinib 14-23 ATP binding cassette subfamily B member 1 Homo sapiens 107-112 19232821-2 2009 In this study, we evaluated the possible interaction of sunitinib with P-glycoprotein (P-gp, ABCB1), multidrug resistance protein 1 (MRP1, ABCC1), breast cancer resistance protein (BCRP, ABCG2) and lung-resistance protein (LRP) in vitro. Sunitinib 56-65 ATP binding cassette subfamily B member 1 Homo sapiens 71-85 19232821-2 2009 In this study, we evaluated the possible interaction of sunitinib with P-glycoprotein (P-gp, ABCB1), multidrug resistance protein 1 (MRP1, ABCC1), breast cancer resistance protein (BCRP, ABCG2) and lung-resistance protein (LRP) in vitro. Sunitinib 56-65 ATP binding cassette subfamily B member 1 Homo sapiens 87-91 19232821-2 2009 In this study, we evaluated the possible interaction of sunitinib with P-glycoprotein (P-gp, ABCB1), multidrug resistance protein 1 (MRP1, ABCC1), breast cancer resistance protein (BCRP, ABCG2) and lung-resistance protein (LRP) in vitro. Sunitinib 56-65 ATP binding cassette subfamily B member 1 Homo sapiens 93-98 19232821-2 2009 In this study, we evaluated the possible interaction of sunitinib with P-glycoprotein (P-gp, ABCB1), multidrug resistance protein 1 (MRP1, ABCC1), breast cancer resistance protein (BCRP, ABCG2) and lung-resistance protein (LRP) in vitro. Sunitinib 56-65 ATP binding cassette subfamily B member 1 Homo sapiens 101-131 19232821-2 2009 In this study, we evaluated the possible interaction of sunitinib with P-glycoprotein (P-gp, ABCB1), multidrug resistance protein 1 (MRP1, ABCC1), breast cancer resistance protein (BCRP, ABCG2) and lung-resistance protein (LRP) in vitro. Sunitinib 56-65 ATP binding cassette subfamily B member 1 Homo sapiens 133-137 33762959-0 2021 Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma. Sunitinib 52-61 ATP binding cassette subfamily B member 1 Homo sapiens 27-32 18971320-0 2009 Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Sunitinib 11-17 ATP binding cassette subfamily B member 1 Homo sapiens 145-159 18971320-0 2009 Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Sunitinib 11-17 ATP binding cassette subfamily B member 1 Homo sapiens 161-166 18971320-0 2009 Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Sunitinib 19-26 ATP binding cassette subfamily B member 1 Homo sapiens 145-159 18971320-0 2009 Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Sunitinib 19-26 ATP binding cassette subfamily B member 1 Homo sapiens 161-166 18971320-3 2009 bioavailability and brain penetration of chemotherapy drugs in animal models, we sought to examine the effect of sunitinib on the ATP-binding cassette (ABC) drug transporters P-glycoprotein (P-gp, ABCB1), the multidrug resistance-associated protein 1 (ABCC1), and ABCG2, which are known to transport a wide variety of anticancer drugs. Sunitinib 113-122 ATP binding cassette subfamily B member 1 Homo sapiens 175-189 18971320-3 2009 bioavailability and brain penetration of chemotherapy drugs in animal models, we sought to examine the effect of sunitinib on the ATP-binding cassette (ABC) drug transporters P-glycoprotein (P-gp, ABCB1), the multidrug resistance-associated protein 1 (ABCC1), and ABCG2, which are known to transport a wide variety of anticancer drugs. Sunitinib 113-122 ATP binding cassette subfamily B member 1 Homo sapiens 191-195 18971320-3 2009 bioavailability and brain penetration of chemotherapy drugs in animal models, we sought to examine the effect of sunitinib on the ATP-binding cassette (ABC) drug transporters P-glycoprotein (P-gp, ABCB1), the multidrug resistance-associated protein 1 (ABCC1), and ABCG2, which are known to transport a wide variety of anticancer drugs. Sunitinib 113-122 ATP binding cassette subfamily B member 1 Homo sapiens 197-202 18971320-4 2009 In this study, we show that sunitinib inhibits P-gp- and ABCG2-mediated efflux of fluorescent substrates in cells overexpressing these transporters. Sunitinib 28-37 ATP binding cassette subfamily B member 1 Homo sapiens 47-51 18971320-5 2009 In 4-day cytotoxicity assays, at a nontoxic concentration (2 microM) sunitinib was able to partially reverse drug resistance mediated by P-gp and completely reverse resistance mediated by ABCG2. Sunitinib 69-78 ATP binding cassette subfamily B member 1 Homo sapiens 137-141 18971320-6 2009 We further show a direct interaction of sunitinib with the substrate binding pocket of these transporters as it inhibited binding of the photoaffinity substrate [(125)I]iodoarylazidoprazosin to P-gp (IC(50) = 14.2 microM) and ABCG2 (IC(50) = 1.33 microM). Sunitinib 40-49 ATP binding cassette subfamily B member 1 Homo sapiens 194-198 33762959-9 2021 Compared with the C allele, the ABCB1 rs1128503 T allele was associated with a decreased risk of sunitinib-induced hypertension but worse progression-free survival (PFS) (ES = 0.44, 95% CI = 0.26-0.77, p = 0.004; ES = 1.36, 95% CI = 1.07-1.73, p = 0.011). Sunitinib 97-106 ATP binding cassette subfamily B member 1 Homo sapiens 32-37 33762959-12 2021 Conclusion: The results indicate that the ABCG2 rs2231142 polymorphism may serve as a predictor of sunitinib-induced thrombocytopenia and HFS in Asians, while the ABCB1 rs1128503 polymorphism may serve as a predictor of sunitinib-induced hypertension, and both the ABCB1 rs1128503 and rs2032582 polymorphisms may serve as predictors of PFS in RCC. Sunitinib 99-108 ATP binding cassette subfamily B member 1 Homo sapiens 265-270 18971320-0 2009 Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Sunitinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 145-159 18971320-0 2009 Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Sunitinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 161-166 33762959-1 2021 Background: ABCG2 and ABCB1 are genes related to the pharmacokinetics of sunitinib and have been associated with its toxicity and efficacy. Sunitinib 73-82 ATP binding cassette subfamily B member 1 Homo sapiens 22-27 33762959-3 2021 This study aimed to evaluate the associations of ABCG2 and ABCB1 polymorphisms with sunitinib-induced toxicity and efficacy in renal cell carcinoma (RCC) by meta-analysis. Sunitinib 84-93 ATP binding cassette subfamily B member 1 Homo sapiens 59-64 24874929-0 2014 Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Sunitinib 132-141 ATP binding cassette subfamily B member 1 Homo sapiens 12-17 24874929-4 2014 We genotyped 11 key SNPs, respectively, in ABCB1, NR1/2, NR1/3 and CYP3A5, involved in sunitinib pharmacokinetics as well as VEGFR1 and VEGFR3, which have been suggested as regulators of sunitinib pharmacodynamics. Sunitinib 87-96 ATP binding cassette subfamily B member 1 Homo sapiens 43-48 32921632-5 2020 On one hand, SAA1 linked to ABCB1 protein, which facilitated sunitinib cellular efflux and diminished drug accumulation. Sunitinib 61-70 ATP binding cassette subfamily B member 1 Homo sapiens 28-33 24566734-5 2014 From univariate analysis, we found that the SNPs in CYP3A4, CYP3A5, and ABCB1 were associated with the clearance of both sunitinib and SU12662. Sunitinib 121-130 ATP binding cassette subfamily B member 1 Homo sapiens 72-77 32041631-8 2020 RESULTS: We demonstrate that YB-1 and ABCB-1 are upregulated in sunitinib-resistant in vitro, ex vivo, in vivo and patient samples compared to the sensitive samples. Sunitinib 64-73 ATP binding cassette subfamily B member 1 Homo sapiens 38-44 32041631-10 2020 Furthermore, our results establish that inhibiting ABCB-1 with elacridar, in addition to sunitinib, has a positive impact on reverting sunitinib-resistance development in in vitro, ex vivo and in vivo models. Sunitinib 135-144 ATP binding cassette subfamily B member 1 Homo sapiens 51-57 29581831-9 2018 Our study provides a population PK model of sunitinib with the ABCB1 genotype as a predictive covariate for apparent oral clearance. Sunitinib 44-53 ATP binding cassette subfamily B member 1 Homo sapiens 63-68 27564227-7 2017 In conclusion, our data showed that the ABCB1 rs2032582 GG genotype was associated with individual adverse events" susceptibility among Japanese patients treated with sunitinib in routine clinical settings. Sunitinib 167-176 ATP binding cassette subfamily B member 1 Homo sapiens 40-45 27485537-0 2016 BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen. Sunitinib 58-67 ATP binding cassette subfamily B member 1 Homo sapiens 8-13 27485537-9 2016 Body surface area (BSA) and ABCB1 polymorphism significantly influenced the CL/F variability of sunitinib: CL/F parent = 13.8 x exp((BSA - 1.75) x 2.08 + (ABCB1 genotype - 0.67) x 0.61), ABCB1-0: wild genotype, 1: mutant genotype. Sunitinib 96-105 ATP binding cassette subfamily B member 1 Homo sapiens 28-33 27485537-9 2016 Body surface area (BSA) and ABCB1 polymorphism significantly influenced the CL/F variability of sunitinib: CL/F parent = 13.8 x exp((BSA - 1.75) x 2.08 + (ABCB1 genotype - 0.67) x 0.61), ABCB1-0: wild genotype, 1: mutant genotype. Sunitinib 96-105 ATP binding cassette subfamily B member 1 Homo sapiens 155-160 27485537-9 2016 Body surface area (BSA) and ABCB1 polymorphism significantly influenced the CL/F variability of sunitinib: CL/F parent = 13.8 x exp((BSA - 1.75) x 2.08 + (ABCB1 genotype - 0.67) x 0.61), ABCB1-0: wild genotype, 1: mutant genotype. Sunitinib 96-105 ATP binding cassette subfamily B member 1 Homo sapiens 155-160 27485537-10 2016 The effect size of ABCB1 mutant genotype and BSA greater than 1.75 m(2) in relation to sunitinib clearance was 31.14 % (p = 0.006) and 22.11 % (p = 0.011), respectively, relative to the reference group. Sunitinib 87-96 ATP binding cassette subfamily B member 1 Homo sapiens 19-24 27485537-11 2016 CONCLUSIONS: Adjusting doses of sunitinib according to BSA and ABCB1 polymorphism in Asian mRCC patients may be recommended for sufficient attainment of a target TTL of sunitinib and its metabolite. Sunitinib 32-41 ATP binding cassette subfamily B member 1 Homo sapiens 63-68 25930089-0 2015 CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Sunitinib 49-58 ATP binding cassette subfamily B member 1 Homo sapiens 11-16 25930089-11 2015 CONCLUSIONS: The confirmation of previously reported associations between polymorphisms in CYP3A5 and ABCB1 with sunitinib toxicity and efficacy, respectively, indicates that genotyping of these genetic variants will be useful for guiding sunitinib treatment. Sunitinib 113-122 ATP binding cassette subfamily B member 1 Homo sapiens 102-107 25930089-11 2015 CONCLUSIONS: The confirmation of previously reported associations between polymorphisms in CYP3A5 and ABCB1 with sunitinib toxicity and efficacy, respectively, indicates that genotyping of these genetic variants will be useful for guiding sunitinib treatment. Sunitinib 239-248 ATP binding cassette subfamily B member 1 Homo sapiens 102-107 31023123-0 2020 Influence of ABCB1 (1236C > T, 2677G > T and 3435C > T) polymorphisms on the transport ability of P-gp-mediated sunitinib in Caco-2 cell line. Sunitinib 121-130 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 31023123-0 2020 Influence of ABCB1 (1236C > T, 2677G > T and 3435C > T) polymorphisms on the transport ability of P-gp-mediated sunitinib in Caco-2 cell line. Sunitinib 121-130 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 31023123-2 2020 The aim of the current research was to observe in vitro the impacts of ABCB1 (1236 C > T, 2677G > T, and 3435C > T) polymorphisms on the efflux activity of P-gp-mediated sunitinib. Sunitinib 179-188 ATP binding cassette subfamily B member 1 Homo sapiens 71-76 31023123-2 2020 The aim of the current research was to observe in vitro the impacts of ABCB1 (1236 C > T, 2677G > T, and 3435C > T) polymorphisms on the efflux activity of P-gp-mediated sunitinib. Sunitinib 179-188 ATP binding cassette subfamily B member 1 Homo sapiens 165-169 31023123-6 2020 The recombinant cell lines transfected with ABCB1 variant alleles (1236 T, 2677T, and 3435T) showed higher resistance to sunitinib compared to cells transfecting with ABCB1 wild-type allele (p < .05). Sunitinib 121-130 ATP binding cassette subfamily B member 1 Homo sapiens 44-49 31023123-7 2020 The intracellular accumulation of sunitinib was significantly decreased in the three types of recombinant cell lines overexpressing ABCB1 variant alleles in comparison of their wild-type cell lines (p < .05). Sunitinib 34-43 ATP binding cassette subfamily B member 1 Homo sapiens 132-137 31023123-9 2020 The P-gp activity in recombinant variant cells is stronger when mediated transport of sunitinib than wild-type counterpart. Sunitinib 86-95 ATP binding cassette subfamily B member 1 Homo sapiens 4-8 31023123-10 2020 P-gp encoded by ABCB1 (1236 T, 2677T, and 3435T) variant alleles may be more efficient to transport sunitinib than wild-type allele. Sunitinib 100-109 ATP binding cassette subfamily B member 1 Homo sapiens 0-4 31023123-10 2020 P-gp encoded by ABCB1 (1236 T, 2677T, and 3435T) variant alleles may be more efficient to transport sunitinib than wild-type allele. Sunitinib 100-109 ATP binding cassette subfamily B member 1 Homo sapiens 16-21 31023123-11 2020 Our observation suggests that ABCB1 (1236 C > T, 2677G > T, and 3435C > T) polymorphisms affect the transport ability of P-gp-mediated sunitinib. Sunitinib 144-153 ATP binding cassette subfamily B member 1 Homo sapiens 30-35 31023123-11 2020 Our observation suggests that ABCB1 (1236 C > T, 2677G > T, and 3435C > T) polymorphisms affect the transport ability of P-gp-mediated sunitinib. Sunitinib 144-153 ATP binding cassette subfamily B member 1 Homo sapiens 130-134 31023123-12 2020 Collectively, ABCB1 polymorphisms may alter the P-gp-mediated sunitinib sensitivity via regulating drug transport. Sunitinib 62-71 ATP binding cassette subfamily B member 1 Homo sapiens 14-19 31023123-12 2020 Collectively, ABCB1 polymorphisms may alter the P-gp-mediated sunitinib sensitivity via regulating drug transport. Sunitinib 62-71 ATP binding cassette subfamily B member 1 Homo sapiens 48-52 30070687-9 2018 BCRP/ABCG2 and MDR1/ABCB1 mRNA expression were linked to decreased progression-free survival after sunitinib treatment. Sunitinib 99-108 ATP binding cassette subfamily B member 1 Homo sapiens 15-19 30070687-9 2018 BCRP/ABCG2 and MDR1/ABCB1 mRNA expression were linked to decreased progression-free survival after sunitinib treatment. Sunitinib 99-108 ATP binding cassette subfamily B member 1 Homo sapiens 20-25 28143610-10 2017 In this case, the patient was homozygous for the ABCG2 421C allele, but was capable of potentially harboring polymorphisms in other genes, such as ABCB1, an efflux pump of sunitinib. Sunitinib 172-181 ATP binding cassette subfamily B member 1 Homo sapiens 147-152 28381801-2 2017 Sunitinib is a substrate of P-glycoprotein (multidrug resistance (MDR)-1/ABCB1) and breast-cancer resistance protein (BCRP/ABCG2). Sunitinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 44-72 28381801-2 2017 Sunitinib is a substrate of P-glycoprotein (multidrug resistance (MDR)-1/ABCB1) and breast-cancer resistance protein (BCRP/ABCG2). Sunitinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 73-78 28381801-3 2017 In this retrospective study, we evaluated the association between sunitinib-induced stomatitis and STAT3, ABCB1, and ABCG2 polymorphisms in patients with metastatic renal cell carcinoma (mRCC). Sunitinib 66-75 ATP binding cassette subfamily B member 1 Homo sapiens 106-111 25778465-0 2016 Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. Sunitinib 108-117 ATP binding cassette subfamily B member 1 Homo sapiens 25-30 25778465-1 2016 The objective of this study was to determine the effect of the CYP3A5 and ATP binding cassette subfamily B member 1 (ABCB1) single-nucleotide polymorphisms on the disposition of sunitinib and SU12662, on clinical response, and on the manifestation of toxicities in Asian metastatic renal cell carcinoma patients. Sunitinib 178-187 ATP binding cassette subfamily B member 1 Homo sapiens 74-115 25778465-1 2016 The objective of this study was to determine the effect of the CYP3A5 and ATP binding cassette subfamily B member 1 (ABCB1) single-nucleotide polymorphisms on the disposition of sunitinib and SU12662, on clinical response, and on the manifestation of toxicities in Asian metastatic renal cell carcinoma patients. Sunitinib 178-187 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 25778465-5 2016 The CC genotype for ABCB1 was associated with a higher sunitinib exposure (76.81 vs 56.55 ng ml(-1), P=0.03), higher risk of all-grade rash (RR 3.00, 95% CI 1.17-7.67) and mucositis (RR 1.60, 95% CI 1.10-2.34) and disease progression than compared with the CT/TT genotype. Sunitinib 55-64 ATP binding cassette subfamily B member 1 Homo sapiens 20-25 26244574-0 2015 Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. Sunitinib 101-110 ATP binding cassette subfamily B member 1 Homo sapiens 15-20 26244574-9 2015 In conclusion, ABCB1 and FLT3 polymorphisms may be helpful in predicting sunitinib toxicities, response and survival benefit in Asian mRCC patients. Sunitinib 73-82 ATP binding cassette subfamily B member 1 Homo sapiens 15-20 25455500-6 2015 We hypothesized that inhibition of multidrug resistant transporters by elacridar (dual inhibitor of P-glycoprotein and ABCG 2) might overcome sunitinib resistance in experimental renal cell carcinoma. Sunitinib 142-151 ATP binding cassette subfamily B member 1 Homo sapiens 100-114 25455500-12 2015 These findings suggest that sunitinib resistance involves multidrug resistance transporters, and in combination with elacridar, can be reversed in renal carcinoma cells by P-glycoprotein inhibition. Sunitinib 28-37 ATP binding cassette subfamily B member 1 Homo sapiens 172-186 26312386-8 2015 Sunitinib stimulated the expression of ABCB1 (ATP-binding cassette, sub-family B [MDR/TAP], member 1), which participates in the accumulation of the drug in autolysosomes and favor its cellular efflux. Sunitinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 39-44 26312386-8 2015 Sunitinib stimulated the expression of ABCB1 (ATP-binding cassette, sub-family B [MDR/TAP], member 1), which participates in the accumulation of the drug in autolysosomes and favor its cellular efflux. Sunitinib 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 46-100 24234588-0 2014 Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. Sunitinib 83-92 ATP binding cassette subfamily B member 1 Homo sapiens 30-35 23462807-7 2013 CONCLUSION: Our results confirm former communications regarding the association between SNPs in ABCB1, NR1/2, NR1/3 and VEGFR3 and sunitinib outcome in clear-cell RCC. Sunitinib 131-140 ATP binding cassette subfamily B member 1 Homo sapiens 96-101 23448320-11 2013 WHAT IS NEW AND CONCLUSION: P-glycoprotein inhibition by sunitinib has been demonstrated. Sunitinib 57-66 ATP binding cassette subfamily B member 1 Homo sapiens 28-42